We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 60

Court denies Myriad’s request to enjoin sale of rival BRCA1BRCA2 tests
  • Shook Hardy & Bacon LLP
  • USA
  • March 20 2014

A federal court in Utah has denied the request for a preliminary injunc- tion filed by Myriad Genetics against a rival company that offered tests


SCOTUS sides with FTC in reverse payment deals
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

A divided U.S. Supreme Court has determined that patent-infringement settlement agreements requiring the patentee to pay the claimed infringer


U.S. Supreme Court issues ruling on patentability of human genes
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The U.S. Supreme Court has determined that while human genes and the information they encode are not patent eligible, despite the effort required to


Australian court finds human gene mutation to be patentable
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be


Federal Courts of Appeals conflict over validity of pay-for-delay deals
  • Shook Hardy & Bacon LLP
  • USA
  • August 2 2012

The Third Circuit Court of Appeals issued a ruling in mid-July that found “any payment from a patent holder to a generic patent challenger who agrees to delay entry into the market must be treated by a factfinder as prima facie evidence of an unreasonable restraint of trade,” thus supporting the Federal Trade Commission’s (FTC’s) view that pay-for-delay deals that settle patent disputes between name-brand pharmaceutical companies and their generic drug competitors violate antitrust law


Fractured Myriad Genetics ruling follows SCOTUS remand
  • Shook Hardy & Bacon LLP
  • USA
  • August 30 2012

Ruling that one plaintiff had standing to seek a declaratory judgment as to the patent eligibility of certain genetic discoveries, the Federal Circuit Court of Appeals has once again reversed in part and affirmed in part a lower court’s determination that isolated DNA molecules and methods of comparing molecules to determine whether a patient’s genes have mutations that could cause breast and ovarian cancer were not patent eligible


Myriad Genetics brings new BRCA1BRCA2 infringement suits
  • Shook Hardy & Bacon LLP
  • USA
  • December 12 2013

Myriad Genetics now reportedly has six pending infringement lawsuits involving its BRCA1 and BRCA2 patents, with Invitae Corp. and Laboratory Corp


CRS report focuses on pharmaceutical patent settlements
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

The Congressional Research Service (CRS) recently issued a report titled "Pharmaceutical Patent Settlements: Issues in Innovation and


Myriad Genetics sues diagnostics company over BRCA1 and BRCA2 testing
  • Shook Hardy & Bacon LLP
  • USA
  • July 11 2013

Just weeks after the U.S. Supreme Court determined that naturally occurring human genes are not patent eligible and thus found certain Myriad


New infringement lawsuit filed to protect BRCA1 and BRCA2 patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 26 2014

Myriad Genetics has brought a new infringement lawsuit against a company offering a next-generation sequencing test that analyzes the BRCA1 and BRCA2